188 papers found
Refreshing results…
The choriocarcinoma cell line JEG-3 upregulates regulatory T cell phenotypes and modulates pro-inflammatory cytokines through HLA-G
Frequent adaptive immune responses against arginase-1
Butyrate and propionate inhibit antigen-specific CD8+ T cell activation by suppressing IL-12 production by antigen-presenting cells
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy
Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma
Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes
The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC.
Cancer and autoimmunity
Survivin
Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial
(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment
Anti-regulatory T cells
The role of dendritic cells in cancer
Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21
Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
Missing publications? Read more about our data sources.